Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

regeneron pharmaceuticals inc. - REGN

REGN

Close Chg Chg %
766.63 18.88 2.46%

Closed Market

785.51

+18.88 (2.46%)

Volume: 671.66K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: regeneron pharmaceuticals inc. - REGN

REGN Key Data

Open

$769.63

 Day Range

765.01 - 786.99

52 Week Range

476.49 - 821.11

 Market Cap

$81.93B

Shares Outstanding

105.70M

 Public Float

101.75M

Beta

0.40

 Rev. Per Employee

N/A

P/E Ratio

18.48

 EPS

$43.12

Yield

45.92%

 Dividend

$0.94

EX-DIVIDEND DATE

Feb 20, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

922.25K

  

REGN Performance

1 Week
 
 3.40%
 
1 Month
 
 -3.76%
 
3 Months
 
 16.59%
 
1 Year
 
 7.98%
 
5 Years
 
 53.64%
 

REGN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 30
Full Ratings ➔

About regeneron pharmaceuticals inc. - REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

REGN At a Glance

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
Phone 1-914-847-7000 Revenue 14.34B
Industry Pharmaceuticals: Major Net Income 4.50B
Sector Health Technology 2025 Sales Growth 0.992%
Fiscal Year-end 12 / 2026 Employees 15,410
View SEC Filings

REGN Valuation

P/E Current 18.684
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.608
Price to Sales Ratio 5.844
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales 4.718
Total Debt to Enterprise Value 0.044

REGN Efficiency

Revenue/Employee 930,752.758
Income Per Employee 292,336.145
Receivables Turnover 2.498
Total Asset Turnover 0.366

REGN Liquidity

Current Ratio 4.766
Quick Ratio 4.218
Cash Ratio 1.971

REGN Profitability

Gross Margin 86.272
Operating Margin 25.747
Pretax Margin 36.469
Net Margin 31.409
Return on Assets 11.49
Return on Equity 14.865
Return on Total Capital 13.264
Return on Invested Capital 13.605

REGN Capital Structure

Total Debt to Total Equity 8.657
Total Debt to Total Capital 8.753
Total Debt to Total Assets 7.329
Long-Term Debt to Equity 8.657
Long-Term Debt to Total Capital 8.642
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Regeneron Pharmaceuticals Inc. - REGN

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
12.17B 13.12B 14.20B 14.34B
Sales Growth
-24.26% +7.76% +8.27% +0.99%
Cost of Goods Sold (COGS) incl D&A
1.71B 2.24B 2.45B 1.97B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
341.40M 421.00M 482.90M 543.70M
Depreciation
303.80M 328.80M 354.00M 364.90M
Amortization of Intangibles
37.60M 92.20M 128.90M 178.80M
COGS Growth
-37.39% +31.63% +9.22% -19.68%
Gross Income
10.47B 10.87B 11.75B 11.70B
Gross Income Growth
-21.58% +3.87% +8.07% -0.44%
Gross Profit Margin
+85.99% +82.89% +82.74% +81.56%
2022 2023 2024 2025 5-year trend
SG&A Expense
5.17B 6.53B 7.52B 8.55B
Research & Development
3.06B 3.99B 4.62B 5.31B
Other SG&A
2.12B 2.54B 2.90B 2.70B
SGA Growth
+16.31% +26.18% +15.28% +13.64%
Other Operating Expense
(89.90M) (2.10M) 53.40M (10.00M)
Unusual Expense
686.50M 539.30M 65.40M 124.90M
EBIT after Unusual Expense
4.70B 3.81B 4.11B 3.57B
Non Operating Income/Expense
219.10M 463.00M 726.70M 1.71B
Non-Operating Interest Income
160.10M 495.90M 711.40M 716.80M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
59.40M 73.00M 55.20M 43.80M
Interest Expense Growth
+3.66% +22.90% -24.38% -20.65%
Gross Interest Expense
59.40M 73.00M 55.20M 43.80M
Interest Capitalized
- - - -
-
Pretax Income
4.86B 4.20B 4.78B 5.23B
Pretax Income Growth
-47.90% -13.57% +13.83% +9.43%
Pretax Margin
+39.91% +32.01% +33.66% +36.47%
Income Tax
520.40M 245.70M 367.30M 725.80M
Income Tax - Current - Domestic
975.90M 675.60M 1.08B 1.03B
Income Tax - Current - Foreign
290.90M 407.90M 43.10M 479.10M
Income Tax - Deferred - Domestic
(800.40M) (841.00M) (940.40M) (860.70M)
Income Tax - Deferred - Foreign
54.00M 3.20M 183.10M 75.30M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
4.34B 3.95B 4.41B 4.50B
Minority Interest Expense
- - - -
-
Net Income
4.34B 3.95B 4.41B 4.50B
Net Income Growth
-46.28% -8.87% +11.61% +2.09%
Net Margin Growth
+35.64% +30.14% +31.07% +31.41%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
4.34B 3.95B 4.41B 4.50B
Preferred Dividends
- - - -
-
Net Income Available to Common
4.34B 3.95B 4.41B 4.50B
EPS (Basic)
40.5079 37.0534 40.8953 43.0679
EPS (Basic) Growth
-46.98% -8.53% +10.37% +5.31%
Basic Shares Outstanding
107.10M 106.70M 107.90M 104.60M
EPS (Diluted)
38.2238 34.7722 38.3371 41.48
EPS (Diluted) Growth
-46.89% -9.03% +10.25% +8.20%
Diluted Shares Outstanding
113.50M 113.70M 115.10M 108.60M
EBITDA
- 5.73B 4.77B 4.66B
EBITDA Growth
- -37.97% -16.72% -2.37%
EBITDA Margin
- +47.05% +36.36% +32.79%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 870.458
Number of Ratings 30 Current Quarters Estimate 9.149
FY Report Date 03 / 2026 Current Year's Estimate 45.242
Last Quarter’s Earnings 11.44 Median PE on CY Estimate N/A
Year Ago Earnings 44.31 Next Fiscal Year Estimate 52.394
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 20 20 23 21
Mean Estimate 9.15 10.67 45.24 52.39
High Estimates 12.73 13.43 58.69 63.16
Low Estimate 5.77 7.36 32.31 27.92
Coefficient of Variance 21.38 12.19 11.64 13.82

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 17 17 17
OVERWEIGHT 4 4 4
HOLD 9 9 8
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Regeneron Pharmaceuticals Inc. - REGN

Date Name Shares Transaction Value
Dec 12, 2025 Daniel P. van Plew EVP & General Mgr, Industrial 21,673 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $701.51 per share 15,203,826.23
Dec 12, 2025 Leonard S. Schleifer Bd. Co-Chair, President & CEO; Director 369,668 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $555.67 per share 205,413,417.56
Dec 12, 2025 Leonard S. Schleifer Bd. Co-Chair, President & CEO; Director 214,523 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $701.51 per share 150,490,029.73
Dec 12, 2025 Leonard S. Schleifer Bd. Co-Chair, President & CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 George Damis Yancopoulos Bd. Co-Chair, President & CSO; Director 442,334 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $555.67 per share 245,791,733.78
Dec 12, 2025 George Damis Yancopoulos Bd. Co-Chair, President & CSO; Director 310,460 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $701.51 per share 217,790,794.60
Dec 12, 2025 George Damis Yancopoulos Bd. Co-Chair, President & CSO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 12, 2025 Andrew J. Murphy EVP Research 47,833 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $701.51 per share 33,555,327.83
Dec 12, 2025 Marion McCourt EVP Commercial 14,349 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $701.51 per share 10,065,966.99

Regeneron Pharmaceuticals Inc. in the News